Primecap Management CO Bei Gene, Ltd. Call Options Transaction History
Primecap Management CO
- $136 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BGNE
# of Institutions
215Shares Held
42MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.29 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.52 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.12 Billion19.1% of portfolio
-
Baillie Gifford & CO3.68MShares$797 Million0.42% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.27MShares$492 Million0.04% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $22.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...